AMENDMENT OF THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of claims in the application.

(Currently amended) A method to reduce recruitment of IDO+ dendritic cells that
inhibit T-cell proliferation to at least one of a tumor or a tumor-draining lymph node in a
subject comprising administering a composition comprising an antibody to CCR6 to the
subject to reduce recruitment of the IDO+ dendritic cells to the at least one of a tumor or
a tumor-draining lymph node, wherein the IDO+ dendritic cells express CCR6 and
elevated levels of indoleamine 2,3-dioxygenase (IDO) (DO), and tumor cells of the at
least one of a tumor or a tumor draining lymph node express MIP-3α.

(Canceled)

- (Original) The method of claim 1, wherein the subject is human.
- 4. (Previously presented) The method of claim 1, wherein the CCR6 antibody blocks the interaction between the CCR6 expressed by the IDO+ dendritic cells and the MIP-3α expressed by tumor cells of the at least one of a tumor or a tumor draining lymph node.
- 5. (Previously presented) The method of claim 1, further comprising the step of determining that IDO+ dendritic cells are recruited to the at least one of a tumor or a tumor-draining lymph node.
- (Previously presented) The method of claim 1, wherein the MIP-3α mediates
 recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor draining
 lymph node.

Claims 7-48 (Canceled)